Sanofi and Owkin partner to develop next-generation biopharma AI agents
Sanofi has entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents. The partnership…
All articles by Salong Debbarma
Salong Debbarma
-
-
EC grants marketing authorisation for IntraBio’s Aqneursa
The European Commission (EC) has granted marketing authorisation for IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann-Pick disease type…
-
Pfizer signs licence agreement with Chai for AI drug discovery
Pfizer and Chai Discovery have agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its…
-
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
Biogen has received the breakthrough therapy designation from the US Food and Drug Administration (FDA) for salanersen (BIIB115), an investigational…
-
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in…
-
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with…
-
AbbVie receives EC approval for Aquipta to treat migraine
AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist,…
-
Roche’s giredestrant secures FDA priority review for breast cancer
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
-
BMS secures FDA acceptance for Camzyos sNDA
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
-
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.…